A genotype-directed dose finding study of irinotecan based on UGT1A1 polymorphisms in metastatic colorectal cancer

A genotype-directed dose finding study of irinotecan based on UGT1A1 polymorphisms in metastatic colorectal cancer - A genotype-directed dose finding study of irinotecan based on UGT1A1 polymorphisms in metastatic colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002166

Enrollment

Registered

2009-08-01

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic colorectal cancer

Interventions

genotype directed dose finding study of irinotecan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: metastatic colorectal cancer PS0,1 no prior chemotherapy of irinotecan

Exclusion criteria

Exclusion criteria: PS2,3 prior chemotherapy of irinotecan

Design outcomes

Primary

Measure	Time frame
adverse events	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026